“…As Fischer suggests, mechanistic studies should focus on applications for PTDs rather than "profiling yet another CDV (cell delivery vector) in unconjugated form" and, according to him, "One of the most exciting applications of CDVs would be the delivery of antibodies against intracellular targets." 121 The appealing idea of creating "transbodies" or "transmabs" by linking a PTD to an antibody had already been promoted earlier by others. 137,138 An extensive use of this exciting approach, however, has been missing so far.…”